Comment on This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound 

This obesity-drug startup emerged from stealth with $290 million and plans to take on Wegovy and Zepbound 

Metsera is taking a ‘Lego kit’ approach to finding a next-generation weight-loss treatment. Biopharma startup Metsera turned heads in April when it emerged from stealth, announcing $290 million in funding from prestigious backers—an all-star roster of scientists and executives—and a portfolio of drug assets all focused on what may be the most lucrative pharmaceutical opportunity ever: obesity.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News